tradingkey.logo

tradingkey.logo
āļ„āđ‰āļ™āļŦāļē


Quanterix Corp

QTRX
āđ€āļžāļīāđˆāļĄāļĨāļ‡āđƒāļ™āļĢāļēāļĒāļāļēāļĢāļ•āļīāļ”āļ•āļēāļĄ
4.030USD
+0.200+5.22%
āļ›āļīāļ” 08-07 16:00ETāļĢāļēāļ„āļēāļĨāđˆāļēāļŠāđ‰āļē 15 āļ™āļēāļ—āļĩ
189.84MāļĄāļđāļĨāļ„āđˆāļēāļ•āļĨāļēāļ”
āļ‚āļēāļ”āļ—āļļāļ™P/E TTM

āļĢāļēāļĒāļĨāļ°āđ€āļ­āļĩāļĒāļ”āđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄāļ‚āļ­āļ‡ Quanterix Corp āļšāļĢāļīāļĐāļąāļ—

Quanterix Corporation is engaged in fueling scientific discovery through ultra-sensitive biomarker detection. The Company’s Simoa technology delivers earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the level of quantification (LoQ). Its precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Its products and services include Simoa Assay Kits, Simoa Dry Blood Extraction Kit, LDTs & Assay Services, Instruments, Simoa Accelerator Laboratory, Homebrew-Custom Assay Development, and Nova Beads. LDTs & Assay Services include Simoa p-Tau 217, Simoa NfL LDT, and LucentAD pTau 217. Its instruments include Simoa HD-X Analyzer-Automated Immunoassays, Quanterix SR-X Biomarker Detection System, and SP-X Imaging and Analysis System.

Quanterix Corp āđ‚āļ›āļĢāđ„āļŸāļĨāđŒ


āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™QTRX
āļŠāļ·āđˆāļ­āļšāļĢāļīāļĐāļąāļ—Quanterix Corp
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļDec 07, 2017
āļ‹āļĩāļ­āļĩāđ‚āļ­Toloue (Masoud)
āļˆāļģāļ™āļ§āļ™āļžāļ™āļąāļāļ‡āļēāļ™471
āļ›āļĢāļ°āđ€āļ āļ—āļāļēāļĢāļĢāļąāļāļĐāļēāļ„āļ§āļēāļĄāļ›āļĨāļ­āļ”āļ āļąāļĒOrdinary Share
āļŠāļīāđ‰āļ™āļ›āļĩāļ‡āļšāļ›āļĢāļ°āļĄāļēāļ“Dec 07
āļ—āļĩāđˆāļ­āļĒāļđāđˆ900 Middlesex Turnpike
āđ€āļĄāļ·āļ­āļ‡BILLERICA
āļ•āļĨāļēāļ”āļŦāļĨāļąāļāļ—āļĢāļąāļžāļĒāđŒNASDAQ OMX - NASDAQ BASIC
āļ›āļĢāļ°āđ€āļ—āļĻUnited States of America
āļĢāļŦāļąāļŠāđ„āļ›āļĢāļĐāļ“āļĩāļĒāđŒ01821
āđ‚āļ—āļĢāļĻāļąāļžāļ—āđŒ16173019400
āđ€āļ§āđ‡āļšāđ„āļ‹āļ•āđŒhttps://www.quanterix.com/
āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™QTRX
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļDec 07, 2017
āļ‹āļĩāļ­āļĩāđ‚āļ­Toloue (Masoud)

āļœāļđāđ‰āļšāļĢāļīāļŦāļēāļĢāļšāļĢāļīāļĐāļąāļ—āļ‚āļ­āļ‡ Quanterix Corp


āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Dr. Masoud Toloue, Ph.D.
Dr. Masoud Toloue, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
355.02K
+20.48%
Mr. William P. (Bill) Donnelly
Mr. William P. (Bill) Donnelly
Executive Chairman of the Board
Executive Chairman of the Board
159.60K
+3.43%
Ms. Vandana Sriram, CPA
Ms. Vandana Sriram, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
34.95K
+3.68%
Ms. Karen A. Flynn
Ms. Karen A. Flynn
Independent Director
Independent Director
33.84K
-47.10%
Mr. Scott Mendel
Mr. Scott Mendel
Director
Director
23.88K
+48.29%
Dr. Myla P. Lai-Goldman, M.D.
Dr. Myla P. Lai-Goldman, M.D.
Director
Director
15.04K
+53.67%
Mr. Jeffrey Thomas (Jeff) Elliott
Mr. Jeffrey Thomas (Jeff) Elliott
Lead Independent Director
Lead Independent Director
11.39K
-139.92%
Dr. Ivana Magov Evi-liebisch, J.D., Ph.D.
Dr. Ivana Magov Evi-liebisch, J.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Garret Hampton, Ph.D.
Dr. Garret Hampton, Ph.D.
Independent Director
Independent Director
--
--
Dr. Alan Sachs, M.D., Ph.D.
Dr. Alan Sachs, M.D., Ph.D.
Independent Director
Independent Director
--
--
āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Dr. Masoud Toloue, Ph.D.
Dr. Masoud Toloue, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
355.02K
+20.48%
Mr. William P. (Bill) Donnelly
Mr. William P. (Bill) Donnelly
Executive Chairman of the Board
Executive Chairman of the Board
159.60K
+3.43%
Ms. Vandana Sriram, CPA
Ms. Vandana Sriram, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
34.95K
+3.68%
Ms. Karen A. Flynn
Ms. Karen A. Flynn
Independent Director
Independent Director
33.84K
-47.10%
Mr. Scott Mendel
Mr. Scott Mendel
Director
Director
23.88K
+48.29%
Dr. Myla P. Lai-Goldman, M.D.
Dr. Myla P. Lai-Goldman, M.D.
Director
Director
15.04K
+53.67%

āļ„āļģāļ–āļēāļĄāļ—āļĩāđˆāļžāļšāļšāđˆāļ­āļĒ

āđƒāļ„āļĢāļ„āļ·āļ­āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™āļŦāđ‰āļēāļ­āļąāļ™āļ”āļąāļšāđāļĢāļāļ‚āļ­āļ‡ Quanterix Corp?


āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™āļŦāđ‰āļēāļ­āļąāļ™āļ”āļąāļšāđāļĢāļāļ‚āļ­āļ‡ Quanterix Corp āđ„āļ”āđ‰āđāļāđˆ: Dr. Masoud Toloue, Ph.D.

āļĄāļĩāļāļĩāđˆāļŠāļ–āļēāļšāļąāļ™āļ—āļĩāđˆāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡ Quanterix Corp (QTRX)?


āļ“ āļ§āļąāļ™āļ—āļĩāđˆ 2026Q1 āļĄāļĩāļŠāļ–āļēāļšāļąāļ™āļˆāļģāļ™āļ§āļ™ 371 āđāļŦāđˆāļ‡āļ—āļĩāđˆāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡ Quanterix Corp āđ‚āļ”āļĒāļĄāļĩāļĄāļđāļĨāļ„āđˆāļēāļĢāļ§āļĄāļ›āļĢāļ°āļĄāļēāļ“ 42.63M āļ„āļīāļ”āđ€āļ›āđ‡āļ™ 90.49% āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļ—āļąāđ‰āļ‡āļŦāļĄāļ” āđ€āļĄāļ·āđˆāļ­āđ€āļ—āļĩāļĒāļšāļāļąāļšāļ§āļąāļ™āļ—āļĩāđˆ 2025Q4 āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡āļŠāļ–āļēāļšāļąāļ™āđ„āļ”āđ‰āđ€āļžāļīāđˆāļĄāļ‚āļķāđ‰āļ™ -4982326.00

āđāļŦāļĨāđˆāļ‡āļĢāļēāļĒāđ„āļ”āđ‰āļŦāļĨāļąāļāļ‚āļ­āļ‡ Quanterix Corp āļ„āļ·āļ­āļ­āļ°āđ„āļĢ?


āđ€āļĄāļ·āđˆāļ­āļ§āļąāļ™āļ—āļĩāđˆ 2026Q1 āļ˜āļļāļĢāļāļīāļˆāļ”āđ‰āļēāļ™ Product revenue āļŠāļĢāđ‰āļēāļ‡āļĢāļēāļĒāđ„āļ”āđ‰āļŠāļđāļ‡āļŠāļļāļ”āđƒāļŦāđ‰āļāļąāļš Quanterix Corp āļ„āļīāļ”āđ€āļ›āđ‡āļ™āļĄāļđāļĨāļ„āđˆāļē 92.94M āđāļĨāļ°āļ„āļīāļ”āđ€āļ›āđ‡āļ™ 67.03% āļ‚āļ­āļ‡āļĢāļēāļĒāđ„āļ”āđ‰āļĢāļ§āļĄ
tradingkey.logo
āļ„āļģāđ€āļ•āļ·āļ­āļ™āļ„āļ§āļēāļĄāđ€āļŠāļĩāđˆāļĒāļ‡: āđ€āļ§āđ‡āļšāđ„āļ‹āļ•āđŒāđāļĨāļ°āđāļ­āļ›āļžāļĨāļīāđ€āļ„āļŠāļąāļ™āļĄāļ·āļ­āļ–āļ·āļ­āļ‚āļ­āļ‡āđ€āļĢāļēāđƒāļŦāđ‰āļ‚āđ‰āļ­āļĄāļđāļĨāļ—āļąāđˆāļ§āđ„āļ›āđ€āļāļĩāđˆāļĒāļ§āļāļąāļšāļœāļĨāļīāļ•āļ āļąāļ“āļ‘āđŒāļāļēāļĢāļĨāļ‡āļ—āļļāļ™āļšāļēāļ‡āļ›āļĢāļ°āđ€āļ āļ—āđ€āļ—āđˆāļēāļ™āļąāđ‰āļ™ Finsights āđ„āļĄāđˆāđ„āļ”āđ‰āđƒāļŦāđ‰āļ„āļģāđāļ™āļ°āļ™āļģāļ—āļēāļ‡āļāļēāļĢāđ€āļ‡āļīāļ™āļŦāļĢāļ·āļ­āļāļēāļĢāđāļ™āļ°āļ™āļģāļœāļĨāļīāļ•āļ āļąāļ“āļ‘āđŒāļāļēāļĢāļĨāļ‡āļ—āļļāļ™āđƒāļ” āđ† āđāļĨāļ°āļāļēāļĢāđƒāļŦāđ‰āļ‚āđ‰āļ­āļĄāļđāļĨāļ”āļąāļ‡āļāļĨāđˆāļēāļ§āđ„āļĄāđˆāļ„āļ§āļĢāļ–āļđāļāļ•āļĩāļ„āļ§āļēāļĄāļ§āđˆāļēāđ€āļ›āđ‡āļ™āļāļēāļĢāđƒāļŦāđ‰āļ„āļģāđāļ™āļ°āļ™āļģāļ—āļēāļ‡āļāļēāļĢāđ€āļ‡āļīāļ™āļŦāļĢāļ·āļ­āļāļēāļĢāđāļ™āļ°āļ™āļģāđ‚āļ”āļĒ Finsights
āļœāļĨāļīāļ•āļ āļąāļ“āļ‘āđŒāļāļēāļĢāļĨāļ‡āļ—āļļāļ™āļĄāļĩāļ„āļ§āļēāļĄāđ€āļŠāļĩāđˆāļĒāļ‡āļ”āđ‰āļēāļ™āļāļēāļĢāļĨāļ‡āļ—āļļāļ™āļ­āļĒāđˆāļēāļ‡āļĄāļēāļ āļĢāļ§āļĄāļ–āļķāļ‡āļāļēāļĢāļŠāļđāļāđ€āļŠāļĩāļĒāđ€āļ‡āļīāļ™āļ•āđ‰āļ™āļ—āļĩāđˆāļĨāļ‡āļ—āļļāļ™āđ„āļ› āđāļĨāļ°āļ­āļēāļˆāđ„āļĄāđˆāđ€āļŦāļĄāļēāļ°āļŠāļģāļŦāļĢāļąāļšāļ—āļļāļāļ„āļ™ āļœāļĨāļāļēāļĢāļ”āļģāđ€āļ™āļīāļ™āļ‡āļēāļ™āđƒāļ™āļ­āļ”āļĩāļ•āļ‚āļ­āļ‡āļœāļĨāļīāļ•āļ āļąāļ“āļ‘āđŒāļāļēāļĢāļĨāļ‡āļ—āļļāļ™āđ„āļĄāđˆāđ„āļ”āđ‰āļšāđˆāļ‡āļšāļ­āļāļ–āļķāļ‡āļœāļĨāļāļēāļĢāļ”āļģāđ€āļ™āļīāļ™āļ‡āļēāļ™āđƒāļ™āļ­āļ™āļēāļ„āļ•
Finsights āļ­āļēāļˆāļ­āļ™āļļāļāļēāļ•āđƒāļŦāđ‰āļœāļđāđ‰āļĨāļ‡āđ‚āļ†āļĐāļ“āļēāļŦāļĢāļ·āļ­āļžāļąāļ™āļ˜āļĄāļīāļ•āļĢāļšāļļāļ„āļ„āļĨāļ—āļĩāđˆāļŠāļēāļĄāļ§āļēāļ‡āļŦāļĢāļ·āļ­āļŠāđˆāļ‡āđ‚āļ†āļĐāļ“āļēāļšāļ™āđ€āļ§āđ‡āļšāđ„āļ‹āļ•āđŒāļŦāļĢāļ·āļ­āđāļ­āļ›āļžāļĨāļīāđ€āļ„āļŠāļąāļ™āļĄāļ·āļ­āļ–āļ·āļ­āļ‚āļ­āļ‡āđ€āļĢāļēāļŦāļĢāļ·āļ­āļŠāđˆāļ§āļ™āđƒāļ”āļŠāđˆāļ§āļ™āļŦāļ™āļķāđˆāļ‡āļ‚āļ­āļ‡āđ€āļ§āđ‡āļšāđ„āļ‹āļ•āđŒāļŦāļĢāļ·āļ­āđāļ­āļ›āļžāļĨāļīāđ€āļ„āļŠāļąāļ™āļĄāļ·āļ­āļ–āļ·āļ­ āđāļĨāļ°āļ­āļēāļˆāđ„āļ”āđ‰āļĢāļąāļšāļ„āđˆāļēāļ•āļ­āļšāđāļ—āļ™āļˆāļēāļāļāļēāļĢāļ—āļĩāđˆāļ„āļļāļ“āļĄāļĩāļ›āļāļīāļŠāļąāļĄāļžāļąāļ™āļ˜āđŒāļāļąāļšāđ‚āļ†āļĐāļ“āļē
ÂĐ āļĨāļīāļ‚āļŠāļīāļ—āļ˜āļīāđŒ: FINSIGHTS MEDIA PTE. LTD. āļŠāļ‡āļ§āļ™āļĨāļīāļ‚āļŠāļīāļ—āļ˜āļīāđŒāļ—āļļāļāļ›āļĢāļ°āļāļēāļĢ